Comparison 8. EGFR inhibitors added to bevacizumab.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Progression‐free survival	6		Hazard Ratio (Random, 95% CI)	1.04 [0.83, 1.29]
2 Overall survival	5		Hazard Ratio (Random, 95% CI)	1.00 [0.69, 1.47]
3 Tumour response rate	4	1310	Odds Ratio (M‐H, Random, 95% CI)	1.20 [0.67, 2.12]
4 Overall grade 3/4 toxicity	3	1831	Odds Ratio (M‐H, Random, 95% CI)	2.57 [1.45, 4.57]
5 Grade 3/4 diarrhoea	5	2434	Odds Ratio (M‐H, Random, 95% CI)	2.58 [1.44, 4.64]
6 Grade 3/4 rash	4	2363	Odds Ratio (M‐H, Random, 95% CI)	67.52 [30.83, 147.85]
7 Grade 3/4 neutropenia	2	1187	Odds Ratio (M‐H, Fixed, 95% CI)	0.97 [0.73, 1.29]